pTVG-HP + pTVG-AR

pTVG-HP + pTVG-AR is a **combination of two DNA-based vaccines** being investigated for use in prostate cancer. Each component is a plasmid DNA vaccine: *pTVG-HP* encodes prostatic acid phosphatase (PAP), while *pTVG-AR* encodes the ligand-binding domain of the androgen receptor (AR)[5][1][4]. These vaccines are designed to elicit T cell immune responses against prostate cancer antigens (PAP and AR) and are administered together, often in combination with PD-1 blockade (e.g., pembrolizumab) to further enhance anti-tumor immunity[3][4][6][8]. Initial trials focus on metastatic, castration-resistant prostate cancer, assessing whether the dual-antigen approach generates more robust and durable T cell responses compared to single-antigen vaccination.